Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes

Clinical and Experimental Dermatology, Supplement

Volumn 28, Issue 1, 2003, Pages 27-29

  Quatresooz, P ^a   Pierard G E ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; IMIQUIMOD; BLOOD CLOTTING FACTOR 8A; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CELL DENSITY; CLINICAL ARTICLE; DENDRITIC CELL; DERMAL DENDROCYTE; DRUG EFFICACY; HUMAN; IMMUNOREACTIVITY; PRIORITY JOURNAL; SKIN CELL; TREATMENT OUTCOME; CASE REPORT; CLINICAL FEATURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PUNCH BIOPSY; FACE TUMOR; IMMUNOLOGY; MIDDLE AGED; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; CARCINOMA, BASAL CELL; DENDRITIC CELLS; FACIAL NEOPLASMS; FACTOR XIIIA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SKIN NEOPLASMS;

EID: 1542750208     PISSN: 09663487     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.28.s1.9.x     Document Type: Article

References (17)

1. Griffin TD, Murphy GF, Sueki H et al. Increased factor XIIIA transglutaminase expression in dermal dendrocytes after treatment with α-hydroxyacids: potential physiologic significance. J Am Acad Dermatol 1996; 34: 196-203.
2. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001; 48: 751-5.
3. Hermanns-Lê T, Nikkels AF, Uhoda I, Petit L, Piérard GE. Imiquimod (Aldara®): an immune response modifier for the skin. Rev Med Liege 2002; 57: 116-8.
4. Arrese JE, Paquet P, Claessens N, Piérard-Franchimont C, Piérard GE. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001; 28: 131-4.
5. Hermanns-Lê T, Paquet P, Nikkels AF, Piérard-franchimont C, Piérard GE. Prolonged imiquimod treatment and graft-versus-host reaction: histological mimicry in the pattern of monocyte-macrophage-dendrocyte lineage skin infiltration. Dermatology 2003; 206: 361-5.
6. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7.
7. Graves D, Valente A. Monocyte chemoattractants produced by malignant cells. J Pathol 1990; 161: 187-8.
8. Zipori D. Stromal cells in tumor growth and regression. Cancer J 1990; 3: 164-9.
9. Kratochwil K. The stroma and the control of cell growth. J Pathol 1986; 149: 23-4.
10. Bugelski PJ, Corwin SP, North SM, Kirsch RL, Nicolson GL, Poste G. Macrophage content of spontaneous metastases at different stages of growth. Cancer Res 1987; 47: 4141-5.
11. Zipori D. Stromal cells in tumor growth and regression. Cancer 1990; 3: 164-9.
12. Piérard-Franchimont C, Arrese JE, Nikkels AF, Al-saleh W, Delvenne P, Pierard GE. Factor XIIIa-positive dermal dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch 1996; 429: 43-8.
13. Arrese JE, Piérard GE. Factor XIIIa-positive dendrocytes and the dermal microvascular unit. Dermatologica 1990; 180: 51-3.
14. Al-Saleh W, Delvenne P, Arrese JE, Nikkels AF, Piérard GE, Boniver J. Inverse modulation of intraepithelial Langerhans' cells and stromal macrophage/dencrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 1995; 427: 41-8.
15. Nestle FO, Nickoloff BJ. A fresh morphological and functional look at dermal dendritic cells. J Cutan Pathol 1995; 22: 385-93.
16. Nickoloff BJ, Griffiths CEM. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J Invest Dermatol 1990; 95: 35s-37s.
17. Quatresooz P, Henry F, Paquet P, Piérard-Franchimont C, Harding K, Piérard GE. Deciphering the impaired cytokine cascades in chronic leg ulcers. Int J Molec Med 2003; 11: 411-8.